Citing the excellent editorial comment by Pekka Mäntyselkä 10 years ago in PAIN on the “Balancing act with geriatric pain treatment”, World Health Organisation predicts that there will be 1.2 billion people above 60 years by 2025, 2 billion by 2050, and in the developed world the very old, aged 80+, is the fastest growing population group. Persistent pain, due to degenerative diseases, osteoarthritis (OA) in particular, becomes more prevalent as a person ages . Comorbidities and polypharmacies increasingly pose dilemmas with increasing risks of interactions and serious side effects. Pain and dysfunction from OA are poorly relieved , but NSAIDs (traditional tNSAIDs and COX-2 specific inhibitors – COX- IBs) are still recommended as cornerstones in the pharmacological treatment of OA .In this issue of the Scandinavian Journal of Pain Patricia Guyot and her co-workers with senior author Andrew Moore, publish an interesting network meta-analysis of diclofenac, ibuprofen, naproxen, indomethacine, and piroxicam for osteoarthritis pain . They analyzed data from 29 previously unpublished randomized, controlled (double-blind) trials (RCTs) from the time before the specific COX- 2-inhibitors appeared and before cardiovascular risks of traditional NSAIDs and the COXIBs were recognized.A network meta-analysis is possible when one drug is compare with
Scandinavian Journal of Pain – de Gruyter
Published: Dec 29, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera